Welcome to your weekly roundup of EP Vantage’s snippets – short takes on smaller news items.
This week, September 19-23, 2016, we had thoughts on the following: Persongen beats Nantkwest (NASDAQ:NK) to the clinic; Chinese group tries to drive two CARs; second me-too success has Teva (NASDAQ:TEVA) looking backwards as well as forwards; J&J's (NYSE:JNJ) PD-1 asset comes out of stealth mode; the end of vepoloxamer surely means the end for Mast Therapeutics; J&J CD123 project suspended – what else is in the pipeline?
These snippets were previously published daily via twitter.
Persongen beats Nantkwest to the clinic
